A New Era in Oncology

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving survival outcomes for patients with cancer. We use our proprietary ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.

Host a BIG PINK Party This October

National Breast Cancer Awareness Month

Our Values

MISSION: To Transform Chemotherapy and Pioneer a New Era in Oncology

"Utilising our proprietary ProTide technology platform we are developing new medicines designed to overcome key cancer resistance mechanisms and improve the survival outcomes for patients."

Hugh S. Griffith

Founder & CEO

Hugh Griffith

PROTIDE
ACELARIN

Our lead product candidate is designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in Phase I, II and III studies.

PROTIDE
NUC-3373

Our second ProTide is designed to overcome the key cancer resistance mechanisms associated with 5-FU. Currently in a Phase I study in patients with advanced solid tumours.

PROTIDE
NUC-7738

A ProTide transformation of cordycepin, a novel nucleoside analog with a unique mode of action and potent anti-cancer activity in preclinical studies. Initiating a Phase I study in 2018.

NEW GENERATION
ANTI-CANCER AGENTS

NuCana's ProTide technology is a powerful platform generating new anti-cancer medicines designed to overcome the key cancer resistance mechanisms.

NUCANA'S
PIPELINE

We take a scientifically driven approach to designing our ProTides to address some of the most significant unmet medical needs in oncology.

LATEST
NEWS

NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018.

European Society for Medical Oncology 2018 Congress

Munich Germany
19-23 October 2018

Investigators will present new data from the Acelarin (NUC-1031) and NUC-3373 programs at the ESMO 2018 Congress.

Leadership

Meet Our Executive Team

Hugh Griffith

Chief Executive Officer

Christopher Wood

Christopher Wood

Chief Medical Officer

Don Munoz

Chief Financial Officer

Global Headquarters

3 Lochside Way
Edinburgh
EH12 9DT
United Kingdom

Telephone: +44 (0)131 357 1111

E-mail: info@nucana.com

U.S. Office

275 Grove Street
Newton, MA 02466

Telephone: +1 617 663 4821

E-mail:info@nucana.com

Contact us